Previous 10 | Next 10 |
2024-01-09 08:21:38 ET More on Pre-market losers $ stocks. Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Financial information for Aclarion, Inc. Seek...
2024-01-08 09:33:32 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering For further details see: CYCC regains compliance wit...
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter fro...
2024-01-08 08:46:55 ET Aclarion ( ACON ) +111% Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan. Harpoon Therapeutics ( HARP ) +110% stock surges as Merck reportedly in talks for $700M acquisition. Ambrx Biopharma ( ...
2024-01-05 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief...
BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agre...
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle - - Retrospective Analysis Identified CDKN2A, CDKN2B an...
2023-12-12 16:17:20 ET More on Cyclacel Pharmaceuticals Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals Historical earnings data for Cyclacel Pharmaceuticals Financial information for Cyclacel Pharmaceuticals For further details see: Cycla...
BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse ...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) fell sharply in today's session following weak quarterly results. Akoustis Technologies po...
Shares of JanOne Inc. (NASDAQ:JAN) rose sharply in today's pre-market trading after the company announced plans to acquire ALT 5 Sigma Inc. Th...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...